Page 25 - 南京医科大学自然版

第45卷第7期 陈宗浩，吴 穹，陈 磊. 溶瘤病毒在乳腺癌治疗中的研究进展［J］.
2025年7月 南京医科大学学报（自然科学版），2025，45（7）：913-924 ·923 ·

tivity of Newcastle disease virus strains AF2240 and V4⁃ synergy in the treatment of breast cancer in vitro and in
UPM in murine myelomonocytic leukemia in vivo［J］. vivo［J］. Cancer Manag Res，2022，14：2749-2761
Leuk Res，2012，36（5）：634-645 ［90］WANG J，LI Y Q，LI S Z，et al. Anti⁃tumor synergistic
［80］RAIHAN J，AHMAD U，YONG Y K，et al. Correction to： effect of a dual cancer ⁃ specific recombinant adenovirus
regression of solid breast tumours in mice by Newcastle and paclitaxel on breast cancer［J］. Front Oncol，2020，10：
disease virus is associated with production of apoptosis re⁃ 244
lated⁃cytokines［J］. BMC Cancer，2019，19（1）：378 ［91］WANG J，TIAN L，BARR T，et al. Enhanced treatment of
［81］AL⁃SHAMMARI A M，SALMAN M I. Antimetastatic and breast cancer brain metastases with oncolytic virus ex⁃
antitumor activities of oncolytic NDV AMHA1 in a 3D pressing anti⁃CD47 antibody and temozolomide［J］. Mol
culture model of breast cancer［J］. Front Mol Biosci， Ther Oncol，2024，32（3）：200824
2024，11：1331369 ［92］HEGDE P S，KARANIKAS V，EVERS S. The where，the
［82］AL⁃ZIAYDI A G，AL⁃SHAMMARI A M，HAMZAH M I， when，and the how of immune monitoring for cancer im⁃
et al. Newcastle disease virus suppress glycolysis pathway munotherapies in the era of checkpoint inhibition［J］.
and induce breast cancer cells death［J］. Virusdisease， Clin Cancer Res，2016，22（8）：1865-1874

2020，31（3）：341-348 ［93］ILETT E，KOTTKE T，THOMPSON J，et al. Prime⁃boost
［83］AL⁃ZIAYDI A G，AL⁃SHAMMARI A M，HAMZAH M I， using separate oncolytic viruses in combination with
et al. Hexokinase inhibition using D⁃Mannoheptulose en⁃ checkpoint blockade improves anti ⁃ tumour therapy［J］.
hances oncolytic Newcastle disease virus ⁃ mediated kill⁃ Gene Ther，2017，24（1）：21-30
ing of breast cancer cells［J］. Cancer Cell Int，2020，20：420 ［94］MAREI H E，HASAN A，POZZOLI G，et al. Cancer immu⁃
［84］ORTEGA ⁃ RIVERA O A，GALLEGOS ⁃ ALCALÁ P，JIM ⁃ notherapy with immune checkpoint inhibitors（ICIs）：po⁃
ÉNEZ M，et al. Inhibition of tumor growth and metastasis tential，mechanisms of resistance，and strategies for rein⁃
by Newcastle disease virus strain P05 in a breast cancer vigorating T cell responsiveness when resistance is ac⁃
mouse model［J］. J Breast Cancer，2023，26（2）：186-200 quired［J］. Cancer Cell Int，2023，23（1）：64
［85］尤赛男，丁 磊，孟浩杰，等. 聚乙二醇化人重组粒细胞 ［95］JIN M，FANG J，PENG J，et al. PD ⁃ 1/PD ⁃ L1 immune
刺激因子防治乳腺癌化疗后骨髓抑制的临床研究［J］. checkpoint blockade in breast cancer：research insights and
南京医科大学学报（自然科学版），2020，40（5）：693- sensitization strategies［J］. Mol Cancer，2024，23（1）：266
696 ［96］TOPALIAN S L，TAUBE J M，ANDERS R A，et al. Mech⁃
YOU S N，DING L，MENG H J，et al. Clinical study on anism ⁃ driven biomarkers to guide immune checkpoint
the prevention and treatment of bone marrow suppression blockade in cancer therapy［J］. Nat Rev Cancer，2016，16
after chemotherapy for breast cancer with pegylated recom⁃ （5）：275-287
binant human granulocyte colony ⁃ stimulating factor［J］. ［97］GAJEWSKI T F. The next hurdle in cancer immunothera⁃
Journal of Nanjing Medical University（Natural Sciences）， py：overcoming the non⁃T⁃cell⁃inflamed tumor microenvi⁃
2020，40（5）：693-696 ronment［J］. Semin Oncol，2015，42（4）：663-671
［86］MORI K M，GIULIANO P D，LOPEZ K L，et al. Pro⁃ ［98］TANG S J，LYLES K V，WANG Y Z，et al. Enhancing the
nounced clinical response following the oncolytic vaccinia efficacy of breast cancer immunotherapy using a smac ⁃
virus GL⁃ONC1 and chemotherapy in a heavily pretreated armed oncolytic virus［J］. Cancers（Basel），2024，16
ovarian cancer patient［J］. Anticancer Drugs，2019，30 （19）：3248
（10）：1064-1066 ［99］MENG L J，WU H T，WU J X，et al. Mechanisms of im⁃
［87］BERRY J T L，MUÑOZ L E，RODRÍGUEZ S R M，et al. mune checkpoint inhibitors：Insights into the regulation of
Doxorubicin conjugation to reovirus improves oncolytic circular RNAS involved in cancer hallmarks［J］. Cell
efficacy in triple⁃negative breast cancer［J］. Mol Ther On⁃ Death Dis，2024，15（1）：3
colytics，2020，18：556-572 ［100］BOURGEOIS⁃DAIGNEAULT M C，ROY D G，AITKEN
［88］BAHREYNI A，MOHAMUD Y，ASHRAF N S，et al. Syn⁃ A S，et al. Neoadjuvant oncolytic virotherapy before sur⁃
ergistic viro ⁃ chemoimmunotherapy in breast cancer en⁃ gery sensitizes triple ⁃ negative breast cancer to immune
abled by bioengineered immunostimulatory exosomes and checkpoint therapy［J］. Sci Transl Med，2018，10（422）：
dual⁃targeted coxsackievirus B3［J］. ACS Nano，2024，18 eaao1641
（5）：4241-4255 ［101］ZHANG H，XIE W M，ZHANG Y N，et al. Oncolytic ade⁃
［89］WANG J，ZUO S T，ZHANG Y，et al. Recombinant onco⁃ noviruses synergistically enhance anti⁃PD⁃L1 and anti⁃
lytic adenovirus combined with cyclophosphamide induces CTLA⁃4 immunotherapy by modulating the tumour micro⁃